DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Anzemet (Dolasetron Mesylate Monohydrate) - Published Studies

 
 



Anzemet Related Published Studies

Well-designed clinical trials related to Anzemet (Dolasetron)

A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. [2011.05]

Inspired oxygen fraction of 0.8 compared with 0.4 does not further reduce postoperative nausea and vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy. [2006.11]

Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. [2006.04]

Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. [2005.11]

Dolasetron versus ondansetron for the treatment of postoperative nausea and vomiting. [2005.02]

Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting. [2004.08]

Droperidol and dolasetron alone or in combination for prevention of postoperative nausea and vomiting after vitrectomy. [2004.08]

Ondansetron versus dolasetron: a comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures. [2004.04]

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. [2003.12.01]

Randomized, double-blind trial of dolasetron versus droperidol for prophylaxis of postoperative nausea and vomiting in patients undergoing TRAM flap breast reconstruction surgery. [2003.11]

Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. [2003.10]

Comparison of oral dolasetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in children. [2003.10]

A comparison of the costs and efficacy of ondansetron and dolasetron in the prophylaxis of postoperative vomiting in pediatric patients undergoing ambulatory surgery. [2003.08]

Dolasetron for the prevention of postoperative vomiting in children undergoing strabismus surgery. [2003.07]

The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron. [2003.02]

[Prevention of post-operative nausea and vomiting. Randomised comparison of dolasetron versus dolasetron plus dexamethasone] [2003.02]

Dolasetron prophylaxis reduces nausea and postanaesthesia recovery time after remifentanil infusion during monitored anaesthesia care for extracorporeal shock wave lithotripsy. [2003.02]

Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing laparoscopic cholecystectomy. [2002.12]

Ondansetron and dolasetron provide equivalent postoperative vomiting control after ambulatory tonsillectomy in dexamethasone-pretreated children. [2002.11]

[Dolasetron reduces pain on injection of propofol] [2002.09]

Dolasetron decreases postoperative nausea and vomiting after breast surgery. [2002.07]

Dexamethasone in combination with dolasetron for prophylaxis in the ambulatory setting: effect on outcome after laparoscopic cholecystectomy. [2002.06]

Dolasetron for preventing postanesthetic shivering. [2002.01]

The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting. [2001.10]

[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo] [2001.07]

Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy. [2001.04]

Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. [2001]

A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. [2000.06]

Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. [2000.02]

Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group. [2000.01]

A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. [2000.01]

[Prophylaxis of nausea and vomiting after pelviscopy. Dolasetron or MCP in comparison with placebo] [1999.10]

[Dolasetron, droperidol and a combination of both in prevention of postoperative nausea and vomiting after extracapsular cataract extraction under general anesthesia] [1999.06]

[Prevention of postoperative nausea and vomiting after hysterectomy with oral dolasetron, intravenous dehydrobenzperidol or a combination of both substances] [1999.06]

Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group. [1999.05]

Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. [1999.05]

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. [1999.01]

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. [1999]

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. [1998.09]

Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group. [1998.03]

The effect of food on the bioavailability of dolasetron mesylate tablets. [1998.01]

Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate. [1998.01]

Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group. [1997.11]

Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group. [1997.09]

Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. [1997.08]

Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery. [1997.08]

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. [1997.08]

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. [1997.05]

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. [1997.05]

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. [1997.03.15]

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. [1997.02]

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting. [1997.02]

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. [1997.02]

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. [1997.01]

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. [1997.01]

A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. [1997]

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. [1996.12]

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. [1996.09]

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. [1996.08]

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. [1996.08]

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. [1996.07]

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. [1996.05]

Multiple-dose, placebo-controlled, phase I study of oral dolasetron. [1996.03]

Single-dose, placebo-controlled, phase I study of oral dolasetron. [1996.03]

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. [1996]

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. [1995.07]

Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. [1995.04]

Well-designed clinical trials possibly related to Anzemet (Dolasetron)

A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis. [2012]

Current review of ramosetron in the prevention of postoperative nausea and vomiting. [2011]

Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. [2008.04]

Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting. [2007]

Drugs for preventing postoperative nausea and vomiting. [2006.07.19]

Paravertebral blocks provide superior same-day recovery over general anesthesia for patients undergoing inguinal hernia repair. [2006.04]

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. [2005.09]

Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. [2005.04]

A comparison of infraclavicular nerve block versus general anesthesia for hand and wrist day-case surgeries. [2004.07]

[Blocking nociceptive afferents by retrobulbar bupivacaine does not decrease nausea and vomiting after propofol-remifentanil anaesthesia] [2003.11]

Antiemetic prophylaxis for office-based surgery: are the 5-HT3 receptor antagonists beneficial? [2003.02]

The effect of anaesthetic technique on postoperative nausea and vomiting after day-case gynaecological laparoscopy. [2002.04]

[Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy] [2002.01]

5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. [2000.10]

[Dimenhydrinate and metoclopramide for prevention of nausea and vomiting following septorhinoplasties in women] [1999.08]

Other research related to Anzemet (Dolasetron)

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. [2009.09]

Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol. [2008.04]

Postoperative nausea and vomiting after surgery for prognathism: Not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol. [2008.03.17]

Dolasetron-induced torsades de pointes. [2007.12]

The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting. [2007.08]

Dolasetron overdose resulting in prolonged QTc interval and severe hypotension: a case report and literature review. [2007.07]

[Dolasetron and shivering : A prospective randomized placebo-controlled pharmaco-economic evaluation.] [2007.01]

[Dolasetron and shivering : A prospective randomized placebo-controlled pharmaco-economic evaluation.] [2006.10.05]

Dolasetron versus ondansetron as single-agent prophylaxis for patients at increased risk for postoperative nausea and vomiting: a prospective, double-blind, randomized trial. [2006.09]

Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. [2006.07]

Coronary vasospasm leading to an acute myocardial infarction after the administration of dolasetron. [2005.02]

Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. [2004.06]

Stability of dolasetron in two oral liquid vehicles. [2003.11.01]

Patient outcomes after therapeutic interchange of dolasetron for granisetron. [2003.05.15]

Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting. [2001.06]

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. [1999.08]

Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. [1999.07]

Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. [1999.06]

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. [1998.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012